- Home
- QNRX vs BDRX Comparison
QNRX vs BDRX Comparison
Compare QNRX & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- BDRX
- Stock Information
- Founded
- QNRX 2018
- BDRX 2000
- Country
- QNRX United States
- BDRX United Kingdom
- Employees
- QNRX N/A
- BDRX N/A
- Industry
- QNRX Medical/Dental Instruments
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- BDRX Health Care
- Exchange
- QNRX Nasdaq
- BDRX Nasdaq
- Market Cap
- QNRX 3.3M
- BDRX 3.6M
- IPO Year
- QNRX N/A
- BDRX N/A
- Fundamental
- Price
- QNRX $8.82
- BDRX $1.15
- Analyst Decision
- QNRX
- BDRX
- Analyst Count
- QNRX 0
- BDRX 0
- Target Price
- QNRX N/A
- BDRX N/A
- AVG Volume (30 Days)
- QNRX 522.9K
- BDRX 3.6M
- Earning Date
- QNRX 05-13-2025
- BDRX 04-11-2025
- Dividend Yield
- QNRX N/A
- BDRX N/A
- EPS Growth
- QNRX N/A
- BDRX N/A
- EPS
- QNRX N/A
- BDRX N/A
- Revenue
- QNRX N/A
- BDRX N/A
- Revenue This Year
- QNRX N/A
- BDRX N/A
- Revenue Next Year
- QNRX N/A
- BDRX N/A
- P/E Ratio
- QNRX N/A
- BDRX N/A
- Revenue Growth
- QNRX N/A
- BDRX N/A
- 52 Week Low
- QNRX $5.01
- BDRX $1.01
- 52 Week High
- QNRX $54.95
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- QNRX 57.93
- BDRX 39.66
- Support Level
- QNRX $8.67
- BDRX $1.01
- Resistance Level
- QNRX $9.30
- BDRX $1.26
- Average True Range (ATR)
- QNRX 0.62
- BDRX 0.12
- MACD
- QNRX 0.03
- BDRX 0.01
- Stochastic Oscillator
- QNRX 56.63
- BDRX 15.22
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.